← All trials
NCT04251182
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 5, 2020
- Primary completion
- Aug 13, 2021
- Completion date
- Aug 13, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 256
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- T3D Therapeutics, Inc.Lead sponsor
- Pharmaceutical Research Associates, Inc. (PRA)Collaborator
- National Institute on Aging (NIA)Collaborator
- T3D Therapeutics, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.